Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection.

ABSTRACT:

Introduction

Gastrointestinal bleeding is a morbid complication of dual antiplatelet therapy (DAPT). We evaluated the extent to which contemporary trials of DAPT included steps to ensure appropriate use of proton pump inhibitor (PPI) gastroprotection and reported rates of PPI use.

Methods

A methodological review of randomized trials comparing varying durations of DAPT after percutaneous coronary intervention.

Results

Among 21 trials, none incorporated protocol procedures or guidance for prescribing PPIs. Five reported rates of PPI use (range 25.6-69.1%).

Discussion

PPI gastroprotection is overlooked in major trials of DAPT. Appropriate use of PPI gastroprotection represents an important opportunity to improve patient safety.

SUBMITTER: Kurlander JE 

PROVIDER: S-EPMC8119932 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature